Question 1

What is Sichuan Kelun-Biotech Biopharmaceutical?

Accepted Answer

Sichuan Kelun-Biotech Biopharmaceutical is a Entity.

Question 2

How often does Sichuan Kelun-Biotech Biopharmaceutical appear in global news?

Accepted Answer

Tracked across 3 news events drawn from 26 articles.

Question 3

When was Sichuan Kelun-Biotech Biopharmaceutical first tracked by Ergen?

Accepted Answer

First tracked on May 30, 2026.

Question 4

When was Sichuan Kelun-Biotech Biopharmaceutical last mentioned in news?

Accepted Answer

Last active on Jul 27, 2026.

Question 5

What is Sichuan Kelun-Biotech Biopharmaceutical's current news sentiment?

Accepted Answer

Aggregate sentiment score: 68 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is Sichuan Kelun-Biotech Biopharmaceutical in global news coverage?

Accepted Answer

Attention score of 6, derived from article volume and coverage intensity across 3 events.

Question 7

What is the most recent event involving Sichuan Kelun-Biotech Biopharmaceutical?

Accepted Answer

Sichuan Kelun-Biotech SKB500 Study Results (Jun 03, 2026, 6 articles).

Question 8

How did the "Sichuan Kelun-Biotech SKB500 Study Results" event impact Sichuan Kelun-Biotech Biopharmaceutical?

Accepted Answer

Sichuan Kelun-Biotech Biopharmaceutical announced positive first-in-human study results for its novel B7-H3 ADC SKB500, which could significantly boost its market position and future revenue streams.

Question 9

How did the "Kelun-Biotech sac-TMT Phase III Results" event impact Sichuan Kelun-Biotech Biopharmaceutical?

Accepted Answer

The company announced positive Phase III clinical trial results for sac-TMT, a core product, which significantly prolonged progression-free survival in NSCLC patients. This enhances its product pipeline and market position.

Question 10

How did the "Kelun-Biotech SKB565 IND Approval" event impact Sichuan Kelun-Biotech Biopharmaceutical?

Accepted Answer

Kelun-Biotech is the central entity; the IND approval for SKB565 advances its pipeline and validates its ADC platform, potentially increasing its market value and competitive position.

Question 11

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.